Literature DB >> 7779710

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells.

C Hennequin1, N Giocanti, V Favaudon.   

Abstract

Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using synchronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial against cells in mitosis, and declined to a minimum with progression to G1. For paclitaxel, cytotoxicity increased with progression through S and G2, peaked at the time of mitosis, and decreased thereafter. Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at prometaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily targets centrosome organisation, leading to abortive mitosis and cell death.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779710      PMCID: PMC2033844          DOI: 10.1038/bjc.1995.232

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

1.  Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese hamster ovary cells.

Authors:  G Bjursell; P Reichard
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

2.  Microtubule assembly in living cells after release from nocodazole block: the effects of metabolic inhibitors, taxol and PH.

Authors:  M De Brabander; G Geuens; R Nuydens; R Willebrords; J De Mey
Journal:  Cell Biol Int Rep       Date:  1981-09

3.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

Authors:  M C Wani; H L Taylor; M E Wall; P Coggon; A T McPhail
Journal:  J Am Chem Soc       Date:  1971-05-05       Impact factor: 15.419

4.  Promotion of microtubule assembly in vitro by taxol.

Authors:  P B Schiff; J Fant; S B Horwitz
Journal:  Nature       Date:  1979-02-22       Impact factor: 49.962

5.  Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins.

Authors:  P B Schiff; S B Horwitz
Journal:  Biochemistry       Date:  1981-05-26       Impact factor: 3.162

6.  Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores.

Authors:  M De Brabander; G Geuens; R Nuydens; R Willebrords; J De Mey
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

7.  Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase.

Authors:  B H Long; C R Fairchild
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

8.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

9.  The centriole cycle in synchronized HeLa cells.

Authors:  E Robbins; G Jentzsch; A Micali
Journal:  J Cell Biol       Date:  1968-02       Impact factor: 10.539

10.  Taxol binds to polymerized tubulin in vitro.

Authors:  J Parness; S B Horwitz
Journal:  J Cell Biol       Date:  1981-11       Impact factor: 10.539

View more
  16 in total

Review 1.  Advanced non-small cell lung carcinoma: the emerging role of docetaxel.

Authors:  C J Langer
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Docetaxel: a review of its use in non-small cell lung cancer.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

3.  Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.

Authors:  M Taron; C Plasencia; A Abad; C Martin; M Guillot
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

Review 4.  Risks and benefits of taxanes in breast and ovarian cancer.

Authors:  L B Michaud; V Valero; G Hortobagyi
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

5.  Inhibition of paclitaxel-induced decreases in calcium signaling.

Authors:  Jennifer H Benbow; Taylor Mann; Camille Keeler; Chengpeng Fan; Michael E Hodsdon; Elias Lolis; Brenda DeGray; Barbara E Ehrlich
Journal:  J Biol Chem       Date:  2012-09-17       Impact factor: 5.157

Review 6.  Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.

Authors:  B Fulton; C M Spencer
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

7.  Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.

Authors:  Yuri Takahashi; Yasuo Miyoshi; Koji Morimoto; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-02-13       Impact factor: 4.322

8.  Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells.

Authors:  M O Trielli; P R Andreassen; F B Lacroix; R L Margolis
Journal:  J Cell Biol       Date:  1996-11       Impact factor: 10.539

9.  Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.

Authors:  G Kramer; S Schwarz; M Hägg; A Mandic Havelka; S Linder
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

10.  Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.

Authors:  Olivier Rixe; Igor Puzanov; Patricia M LoRusso; Roger B Cohen; John C Morris; Olugbenga O Olowokure; Jian Y Yin; Séverine Doroumian; Liji Shen; Anthony J Olszanski
Journal:  Anticancer Drugs       Date:  2015-08       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.